+971.7%
MRNA vs GSK
+83.0%
+888.7%
-95.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.3% | -1.6% | +2.9% | +2.2% |
| 7D | -13.8% | -4.7% | -9.1% | -11.4% |
| 30D | -17.7% | -4.7% | -13.0% | -15.5% |
| 3M | +14.3% | -8.8% | +23.1% | +20.9% |
| 6M | +336.0% | -4.6% | +340.6% | +355.0% |
| YTD | +575.9% | +1.0% | +574.9% | +586.2% |
| 1Y | +724.4% | +6.9% | +717.5% | +718.1% |
| 3Y | +160.8% | +52.5% | +108.2% | +125.1% |
| 5Y | -24.4% | +40.3% | -64.7% | -34.0% |
| All | +971.7% | +83.0% | +888.7% | +618.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling